P5-09-05: Non-Palpable Lesions Findings in a Breast Cancer Opportunistic Screening in South Brazil.

Abstract

Abstract Introduction: Today breast cancer is a major public health challenge in developing countries with increasing mortality rates due to the lack of early detection programs and access to care. Mammography has been considered the most sensitive test for breast non-palpable lesions. The Brazilian National policy recommends mammography from age 50 and every two years. This study investigates only radiological findings in a set of women seeking for long term breast care surveillance. Objectives: To evaluate patients characteristics of cases with non-palpable breast lesions. Material and method: A prospective and transversal study was undertaken between March,2009 and April,2010 on 110 women with non-palpable breast lesions, diagnosed by mammography or ultrasound. Histo-pathological evaluation was performed in core biopsy specimen. The following variables were studied: pregnancy, parity, menarche, menopause, hormone replacement therapy, breast lesion location, tumor size, histopathology findings, mammographic and ultrasound classification — BI-Rads. Results: 23,7% (n=26/110) out of 110 women were diagnosed with breast cancer and 76,3% (n=84/110) were diagnosed with benign mammary pathology. Mammography, according BIRads classification, strongly suggested (p<0,000) the presence of benign and malign pathologies. In the breast cancer group, 14 were diagnosed with stage 1 (TNM), compared to the official data from INCA where stage I is 10% of the cases. Conclusion: Mammographic screening reduces mortality by 30% after 50 years of age and also provides important benefit (20%) in younger women (40-49). Our study showed a cancer detection rate of 25,7% and 34,6%, respectively, demonstrating the importance of screening also in younger ages. Overall, the rate of biopsy positive was very satisfactory (1 out of 4 cases). Among the studied non-palpable breast lesions, our findings resulted in 53.8% stage I breast cancers (TNM) which reinforces the urgent need of a structured screening program in Brazil to save more lives. Financial support: Avon Institute. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-09-05.